Related Experiment Video

Updated: Jun 23, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction

A Mark Richards1, M Gary Nicholls, Eric A Espiner

  • 1Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand. mark.richards@cdhb.govt.nz

Circulation
|May 29, 2003
PubMed

Insights

Plasma B-type natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) are key predictors of adverse events after myocardial infarction. Combining BNP and LVEF offers superior risk stratification for improved patient outcomes.

Area of Science:

  • Cardiology
  • Biomarkers
  • Prognostic Indicators

Background:

  • Plasma B-type natriuretic peptide (BNP) independently predicts mortality, heart failure, and myocardial infarction in acute coronary syndromes.
  • Left ventricular ejection fraction (LVEF) is crucial for prognosis and therapeutic response after acute cardiac injury.

Purpose of the Study:

  • To evaluate the prognostic utility of concurrent measurements of BNP, amino-terminal BNP (N-BNP), norepinephrine, and radionuclide LVEF in a large cohort of acute myocardial infarction patients.
  • To determine if combined BNP/N-BNP and LVEF measurements improve risk stratification compared to individual markers.

Main Methods:

  • Analysis of a cohort of 666 patients with acute myocardial infarction.
  • Concurrent measurement of plasma BNP, N-BNP, norepinephrine, and radionuclide LVEF.
  • Statistical analysis to assess independent predictive value and combined risk stratification efficacy.

Main Results:

  • Both B-type peptides (BNP, N-BNP) and LVEF independently predicted death, heart failure, and new myocardial infarction (P<0.001).
  • Combined BNP/N-BNP and LVEF significantly improved risk stratification beyond individual markers.
  • Elevated N-BNP/BNP predicted new myocardial infarction specifically in patients with LVEF <40%.

Conclusions:

  • Plasma N-BNP (or BNP) and LVEF are complementary, independent predictors of major adverse events post-myocardial infarction.
  • Combined measurement of N-BNP/BNP and LVEF provides substantially enhanced risk stratification.
Abstract

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...